Treatment of Inflammatory Bowel Disease with Biologics
297 References Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. Xavier RJ, Podolsky DK. Unrav ...
298 Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A pilot study of treatment of active ulc ...
299 Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of active Crohn’s disease with MLN0002, ...
300 Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382(9904):1587–99. Beaugerie ...
301 Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion ...
© Springer International Publishing AG 2018 303 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
304 Leukocyte Trafficking Antagonists Vedolizumab (Anti-α 4 β7 Integrin, Monoclonal Ab, IV Route, UC/CD) Vedolizumab, a monoclon ...
305 ulcerative colitis [ 2 ]. After induction, vedolizumab-treated patients had greater rates of response, remission, and mucosa ...
306 detected and its mechanism of action should not increase the risk of PML, this was a short-term induction study, thus requir ...
307 endpoint, a reduction of 70 points in the CDAI at week 12, and this was attributed to a high placebo response rate. A statis ...
308 the study was deemed as preliminary by the authors [ 18 ]. The reasons were size of the study (around 65 patients per group) ...
309 specifically seek this group as a population of interest. A phase III randomized clinical trial in ulcerative colitis is rec ...
310 Filgotinib (Anti-JAK1, Small Molecule, po Route, UC/CD) Similar to tofacitinib, filgotinib is an oral small molecule directe ...
311 drug appears to work locally and not bioavailable systemically. Last, and perhaps most novel, is that clinical remission was ...
312 Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N E ...
313 Feagan B. Update on tofacitinib for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12:572–4. Sandborn WJ, Sa ...
© Springer International Publishing AG 2018 315 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
316 Choice of Biologic Agents There are eight FDA-approved biologic agents to treat IBD, generally indicated for patients with a ...
317 and disadvantages of the different options and be involved in the decision as to which biologic may be best for them [ 10 ]. ...
318 [NYHA] functional class III/IV) or a personal history of multiple sclerosis or optic neuritis [ 3 – 6 ]. Integrin receptor a ...
«
8
9
10
11
12
13
14
15
16
17
»
Free download pdf